{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', \"Wiersinga WM, Perros P, Kahaly GJ, et al. Clinical assessment of patients with Graves'\", \"orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists,\", 'specialists and clinical researchers. European journal of endocrinology. 2006; 155(3): 387-9.', \"Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for Graves'\", 'orbitopathy: efficacy and morbidity. The Journal of clinical endocrinology and metabolism.', '2011; 96(2): 320-32.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 115 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '17 APPENDICES', '17.1 Administrative Appendix', 'This appendix provides names and contact information for the study administrative structure.', 'The IRB/IEC must be notified of changes that are made to this section, but IRB/IEC review or', 'approval of these changes is not required. Changes made in this section will be dated but will not', 'be assigned a protocol amendment number.', 'Medical Monitor', 'Senior Medical Director', 'Horizon Pharma USA, Inc.', '150 S. Saunders Road', 'Lake Forest, IL 60045', 'Mobile telephone number:', 'Business telephone number:', 'Fax number:', 'Email:', 'Sponsor', 'Representative', 'Horizon Pharma USA, Inc.', '150 S. Saunders Road', 'Lake Forest, IL 60045', 'Mobile telephone number:', 'Fax number:', 'Email:', 'Sponsor Contact for', 'Serious Adverse Event Reporting', 'Telephone number:', 'Fax:', 'Email:', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 116 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '17.2 Proptosis (Exophthalmometry) Method', '1. Choose a Hertel exophthalmometer provided by the Study Sponsor for consistency in', 'measurement with a snug mechanism and preferably a square angle where it sits against', 'the orbital rim (a).', '2. Open it wider than required.', '3. Sit opposite the patient and at the same level.', '4. Keep the patient relaxed, avoiding breath holding and excessive eyelid retraction.', '(c)', '(b)', '(a)', 'move adjustable part to left side of', 'patient only when right size is', 'stabilised firmly in position', '5.', \"Position left foot of Hertel against the patient's right lateral orbital rim, at level of lateral\", 'canthus (b).', 'It should sit firmly as medially as possible, but outside lateral canthus and without', 'distorting position of globe.', '6. Slide right foot medially into identical position on left orbital rim (c). This will feel tight', 'and slightly uncomfortable, but minimizes potential side slippage of Hertel.', \"7. Ask patient to fix their right eye on your left eye while you occlude the patient's left\", 'visual axis with your right thumb. In this position, align the instrument such that the', \"vertical mark (or cone) is aligned with the manufacturer's pre-marked position on the\", 'ruler. Once aligned, rotate the instrument slightly around the horizontal plane such as to', 'view the apex of the cornea in the mirror. Record the position of the corneal apex on the', 'ruler. This is Hertel value.', '8. To record the left eye, hold the instrument stationary and move your head. Then use your', 'right eye to record the patients left eye. Again, the opposite visual axis is occluded by', 'your left thumb, while the patient is asked to fix on your right eye. Ensure that the', 'corneal apex is measured by rotating the instrument slightly around the horizontal plane', 'if required.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 117 of 118']\n\n###\n\n", "completion": "END"}